放疗联合表皮生长因子受体酪氨酸激酶抑制剂治疗非小细胞肺癌的临床效果

目的 探讨放疗联合表皮生长因子受体(epithelial growth factor receptor,EGFR)酪氨酸激酶抑制剂在非小细胞肺癌(non-small cell lung cancer,NSCLC)治疗中的临床价值.方法 随机选取采用放疗联合表皮生长因子受体酪氨酸激酶抑制剂进行治疗的非小细胞肺癌患者30例,按照实体瘤疗效评价标准对患者治疗的疗效进行评价,观察并记录患者的不良反应,并对患者进行预后影响因素分析及生存分析.结果 患者接受放疗联合EGFR-TKI治疗后,完全缓解1例,部分缓解11例,疾病稳定16例,疾病恶化2例,疾病控制率为93.33%(28/30).吸烟、非腺癌、服药前肿瘤大小≥5 cm患者的疾病控制率明显低于不吸烟、腺癌、服药前肿瘤大小<5 cm的患者,且差异具有统计学意义(P<0.05).生存分析结果显示NSCLC患者的中位无进展生存时间为5个月,中位总生存时间为16个月.服药前肿瘤大小<5 cm患者、不吸烟患者的中位无进展生存时间及中位总生存时间都优于服药前肿瘤大小≥5 cm的患者、吸烟患者,且差异具有统计学意义(P<0.05).出现皮疹的患者有7例,皮肤瘙痒的患者6例,进行针对性治疗后不良反应均消失.结论 放疗联合表皮生长因子受体酪氨酸激酶抑制剂在非小细胞肺癌治疗中发挥着重要作用,腺癌、不吸烟、小病灶是对非小细胞肺癌进行治疗的有利因素.

Clinical Efficacy of Radiotherapy Combined with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Non-small Cell Lung Cancer

Objective To study the clinical efficacy of radiotherapy combined with epidermal growth factor receptor ( EGFR) tyrosine kinase inhibitors for non-small cell lung cancer ( NSCLC) . Methods 30 cases of radiotherapy combined with epidermal growth factor receptor tyrosine kinase inhibitor for non-small cell lung cancer were randomly selected,according to RE-CIST criteria the efficacy of the treatment of patients evaluated,observed and recorded adverse reactions in patients,and analyze prognostic factors and survival analysis of patients. Results The patients receiving radiotherapy with EGFR-TKI treatment,com-plete remission in 1 case,11 cases of partial remission,stable disease in 16 cases,2 cases of disease progression,disease control rate was 93. 33%(28/30),smoking,non-adenocarcinoma,before taking control of the disease in patients with tumor size≥5 cm significantly lower than non-smokers,adenocarcinoma,before taking the tumor size <5 cm patients,and the difference was statisti-cally significant (P <0. 05). Survival analysis showed that NSCLC patients,the median progression-free survival time was 5 months,median overall survival time was 16 months. Before taking the tumor size <5 cm median progression-free survival time and overall survival were better than before taking the median tumor size≥5 cm patients,and the difference was statistically sig-nificant (P<0. 05);no smoking median progression-free survival and overall survival time median superior to patients with a his-tory of smoking,and the difference was statistically significant (P<0. 05);patients had a rash of seven cases,6 cases of patients with pruritus,targeted therapy after the adverse reactions disappeared. Conclusion Radiotherapy combined with ( EGFR) tyro-sine kinase inhibitors for NSCLC is effective,do not smoke,small lesions are favorable factors for non-small cell lung cancer treat-ment.